Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
|
Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturers:
|
Lariam
Mefloquine hydrochloride 274.09mg equivalent to mefloquine 250mg
Tablet
Roche Products (NZ) Limited
F. Hoffmann-La Roche Limited, Basel, Switzerland
Cenexi SAS, Fontenay-sous-Bois, France
|
|
Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturer:
|
Myprax
Venlafaxine hydrochloride 42.5mg equivalent to venlafaxine 37.5mg
Modified release capsule
REX Medical Limited
Cipla Limited, Daund, India
|
|
Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturer:
|
Myprax
Venlafaxine hydrochloride 85mg equivalent to venlafaxine 75mg
Modified release capsule
REX Medical Limited
Cipla Limited, Daund, India
|
|
Product:
Active Ingredient:
Dosage Form:
New Zealand Sponsor:
Manufacturer:
|
Myprax
Venlafaxine hydrochloride 170mg equivalent to venlafaxine 150mg
Modified release capsule
REX Medical Limited
Cipla Limited, Daund, India
|
Dated this 12th day of January 2017.
DEREK FITZGERALD, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).
Gazette.govt.nz